The Motley Fool·2d ago
Here's the 1 Stock I'd Most Want to Buy If the Market CrashesViking's ongoing phase 3 trials are the key to unlocking value for shareholders. Its lead drug, VK2735, has demonstrated impressive results in a phase 2 trial.
Viking Therapeutics reports no revenue across the periods provided, while operating losses widened from $34.1M in 2024Q2 to $187.1M in 2026Q3, driven primarily by R&D expansion to $166.8M per quarter.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 28, 2026 | -$1.55-46.2% vs -$1.06 | — vs — |
Q3 2026 Jul 29, 2026 | -$1.10+10.6% vs -$1.23 | — vs — |
Q2 2026 Apr 29, 2026 | -$1.37-35.6% vs -$1.01 | — vs — |
Q1 2026 Feb 11, 2026 | -$1.38-55.1% vs -$0.89 | — vs $2M |
Viking's ongoing phase 3 trials are the key to unlocking value for shareholders. Its lead drug, VK2735, has demonstrated impressive results in a phase 2 trial.
The weight loss drug market is on track to reach nearly $100 billion by the end of the decade. Viking has a candidate, in two formulations, involved in phase 3 studies.
Tracking the S&P 500 may not be optimal anymore, and there can be better ways for investors to gain a mix of dividends, stability, and growth.
SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the Stifel 2026 Healthcare Conference, Truist 2026 BioPharma Symposium, UBS Global Biopharma Conference, Jefferies Global Healthcare Conference, and the Piper Sandler 38th Annual Healthcare Conference in November and December. Details of the company's participation are as follows: Stifel 2026 Healthcare Conference Details: Viking management will participate in a fireside chat and investor meetings.Conference Dates: November 10-12, 2026Fireside Chat Date/Time: Wednesday, November 11th, 10:40 am – 11:10 am ETLocation: New York, NY Truist 2026 BioPharma Symposium Details: Viking management will participate in investor meetings.Conference Date: November 12, 2026Location: New York, NY UBS Global Biopharma Conference Details: Viking management will participate in a fireside chat and investor meetings.Conference Dates: November 16-17, 2026Fireside Chat Date/Time: Tuesday, November 17th, 10:40 am - 11:10 am ETLocation: London, UK Jefferies Global Healthcare Conference Details: Viking management will participate in a fireside chat and investor meetings.Conference Dates: November 16-19, 2026Fireside Chat Date/Time: Wednesday, November 18th, 2:00 pm – 2:25 pm GMTLocation: London, UKWebcast available Piper Sandler 38th Annual Healthcare Conference Details: Viking management will participate in a fireside chat and investor meetings.Conference Dates: December 1-3, 2026Fireside Chat Date/Time: Wednesday, December 2nd, 2:00 pm - 2:25 pm ETLocation: New York, NYWebcast available A live webcast of the Jefferies and Piper Sandler fireside chats may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts.
Benchmark VKTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Viking Therapeutics, Inc. (VKTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $26.84 | $3.13B | -5.05 | — | — | -117.35% | — | |
| $2.47 | $170.85M | -2.38 | — | — | -51.01% | — | |
| $131.73 | $10.84B | -37.73 | -16.72% | -341.87% | -22.39% | — | |
| $20.35 | $1.17B | -6.87 | — | — | -16.91% | — | |
| $75.99 | $6.7B | -37.40 | 254.7% | -2928.43% | -18.69% | — | |
| $40.31 | $179B | 10.58 | 6.43% | 33.94% | 54.09% | 4.3% |
Viking Therapeutics, Inc. (VKTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Viking Therapeutics, Inc. (VKTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 28, 2026·SEC
Jul 29, 2026·SEC
May 26, 2026·SEC
Get notified when VKTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Viking Therapeutics, Inc. (VKTX) stock FAQ — growth, dividends, profitability & financials explained
No. Viking Therapeutics, Inc. (VKTX) reported a net loss of $627.2M over the trailing twelve months.
Viking Therapeutics, Inc. (VKTX) had a return on equity (ROE) of -117.3% over the trailing twelve months. A negative ROE means the company lost money over the period.
Viking Therapeutics, Inc. (VKTX) had negative free cash flow of $462.6M over the trailing twelve months.
